<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JBM</journal-id><journal-title-group><journal-title>Journal of Biosciences and Medicines</journal-title></journal-title-group><issn pub-type="epub">2327-5081</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jbm.2024.121005</article-id><article-id pub-id-type="publisher-id">JBM-130414</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  Extracellular Vesicles from Mesenchymal Stromal Cells (imEVs) Improve Cold Preservation of Isolated Mitochondria
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xianpeng</surname><given-names>Jiang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sergey</surname><given-names>Rodin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ken</surname><given-names>Braesch-Andersen</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Catherine</surname><given-names>C. Baucom</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Karl-Henrik</surname><given-names>Grinnemo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Brent</surname><given-names>Segal</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Department of Surgical Sciences, Division of Cardiothoracic Surgery, Cardio-Thoracic Translational Medicine (CTTM) Laboratory, Uppsala University, Uppsala University Hospital, Uppsala, Sweden</addr-line></aff><aff id="aff1"><addr-line>Elliott Mitochondrial Center, Sallie Astor Burdine Breast Foundation, Baton Rouge, Louisiana, USA</addr-line></aff><aff id="aff3"><addr-line>Mitosense Inc., Boston, Massachusetts, USA</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>01</month><year>2024</year></pub-date><volume>12</volume><issue>01</issue><fpage>52</fpage><lpage>63</lpage><history><date date-type="received"><day>7,</day>	<month>December</month>	<year>2023</year></date><date date-type="rev-recd"><day>8,</day>	<month>January</month>	<year>2024</year>	</date><date date-type="accepted"><day>11,</day>	<month>January</month>	<year>2024</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Mitochondrial organelle transplantation (MOT) is an innovative strategy for the treatment of mitochondrial dysfunction such as cardiac ischemic reperfusion injuries, Parkinson’s diseases, brain and spinal cord injuries, and amyotrophic lateral sclerosis (ALS). However, one of the major challenges for widespread usage is a methodology for preservation of isolated mitochondria. Extracellular vesicles (EVs) are phospholipid bilayer-enclosed vesicles released from cells. EVs carry a cargo of proteins, nucleic acids, lipids, metabolites, and even organelles such as mitochondria. 
  Purpose: To test if EVs enhance the stability of isolated mitochondria. 
  Methods: We mixed isolated mitochondria of fibroblasts with EVs of mesenchymal stromal cells (imEVs) (9:1 in volume) and stored the mixture at 2&amp;deg;C - 6
  &amp;deg;C for different time periods. We measured morphology, mitochondrial membrane potential (MMP) and mitochondrial ATP content at 0, 2, 5 days. 
  Key findings: After 2 days of storage, the mito-chondria without imEVs lost approximate 70% MMP (RFU: 1822 &#177; 68), compared to the fresh mitochondria (RFU: 5458 &#177; 52) (p &lt; 0.01). However, MMP of the mitochondria mixed with imEVs (RFU: 6786 &#177; 291) was even slightly higher than MMP of the fresh mitochondria (RFU: 5962 &#177; 222) (p &gt; 0.05). In agreement with MMP, mitochondria without imEVs lost significant mitochondrial ATP content (p &lt; 0.01), but the mitochondria with imEVs addi-tion preserved at least 90% mitochondrial ATP (p &gt; 0.05), after 2 days of cold storage, compared to fresh mitochondria. Microscopy showed that imEVs promoted aggregation of isolated mitochondria. 
  Summary: The preliminary data showed that imEVs enhanced the stability of isolated mitochondria in cold storage.
 
</p></abstract><kwd-group><kwd>Mitochondria</kwd><kwd> Extracellular Vesicles</kwd><kwd> Mitochondrial Preservation</kwd><kwd> MOT</kwd><kwd> imEVs</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>In eukaryotic cells, mitochondria are well known as the powerhouse which generates ATP by oxidative phosphorylation (OXPHOS). They also play an important role in synthesis of iron-sulfur clusters and heme, β-oxidation of fatty acids, the urea cycle, and homeostasis of calcium, iron and reactive oxygen species (ROS) [<xref ref-type="bibr" rid="scirp.130414-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.130414-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.130414-ref3">3</xref>] . Mitochondrial dysfunction plays an important role in many diseases such as cardiovascular disease, metabolic disease, neurodegenerative disease, etc. [<xref ref-type="bibr" rid="scirp.130414-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.130414-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.130414-ref5">5</xref>] . Traditional drugs or genes have difficulty entering specific sub-compartments of mitochondria. Moreover, the diverse nature of gene mutations among patients makes it impossible to develop one drug to correct mitochondrial dysfunction. In recent years, mitochondrial organelle transplantation (MOT) has shone a new light on therapeutic intervention that benefits neuronal survival and regeneration for neurodegenerative diseases, stroke and CNS injury [<xref ref-type="bibr" rid="scirp.130414-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.130414-ref7">7</xref>] . McCully et al. reported the first clinical trial of mitochondrial transplantation therapy. They performed an autologous mitochondrial transplantation for myocardial ischemia–reperfusion injury of pediatric patients who required extracorporeal membrane oxygenation (ECMO) [<xref ref-type="bibr" rid="scirp.130414-ref8">8</xref>] . Elliott et al. reported a case study that MOT significantly improved leg muscle strength and recovered all sensory sensations in a deteriorated ALS patient [<xref ref-type="bibr" rid="scirp.130414-ref6">6</xref>] . It has been reported that the isolated mitochondria lost significant activity when stored on ice for more than 1 hour, thus a rapid operation is essential during clinical trial [<xref ref-type="bibr" rid="scirp.130414-ref9">9</xref>] . Cold storage and cryopreservation of mitochondria haven’t been successful for long term storage, leading to the decrease in respiratory capacity and damage of mitochondrial membrane structure over time [<xref ref-type="bibr" rid="scirp.130414-ref10">10</xref>] . Thus, the preservation of mitochondria is a significant challenge for MOT.</p><p>Membranous extracellular vesicles (EVs), including exosomes, microvesicles and apoptotic bodies (ApoBDs), facilitate intercellular communication following their release from donor cells and subsequent internalization into recipient cells. EVs can encapsulate small portions of the subjacent cytosol and create a heterogeneous population of phospholipid-walled vesicles. ApoBDs are the largest EVs in size and contain a wide variety of cellular components: micronuclei, chromatin remnants, cytosol portions, degraded proteins, DNA fragments, or even intact organelles [<xref ref-type="bibr" rid="scirp.130414-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.130414-ref12">12</xref>] . MSC-EV-mediated mitochondrial transfer from the EVs to injured alveolar epithelia and endothelia has been reported. In the acute respiratory distress syndrome (ARDS) models, MSC-EVs improve alveolar–capillary barrier properties through restoration of mitochondrial functions at least partially via mitochondrial transfer [<xref ref-type="bibr" rid="scirp.130414-ref13">13</xref>] . EVs can be stored at −20˚C without losing the efficacy of inner cellular components including mitochondria. We hypothesize that EVs matrix could preserve the function of cellular components and enhance the stability of isolated mitochondria.</p><p>We mixed the EVs of mesenchymal stromal cells (imEVs) with isolated mitochondria of fibroblasts, and stored the mixture at 2˚C - 6˚C for different times. We measured morphology, mitochondrial membrane potential (MMP) and mitochondrial ATP content. The preliminary data showed that imEVs prolong the survival of isolated mitochondria in cold storage.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Isolation, Primary Culture and Cryopreservation of Human Fibroblasts</title><p>Collection of human skin tissue was approved by Western IRB (Protocol#20203104). All tissue pieces were digested by 3% collagenase type 3 (Worthington Biochemical Corporation, Lakewood, NJ, USA) at 37˚C for 5 hours in a sterile stirring chamber. The liquid was transferred into a sterile 50 ml centrifuge tube and centrifuged for 5 minutes at 400 g. Supernatant was removed. Cell pellet was resuspended in 30 ml pre-warmed (37˚C) complete alpha minimum essential media (alpha MEM) (GIBCO, Carlsbad, CA, USA) containing 5% human platelet lysate (HPL) (Biological Industries, Cromwell, CT, USA) and 0.05 mg/ml gentamicin (GIBCO, Carlsbad, CA, USA). Cells was cultured at 37˚C in 5% CO<sub>2</sub> incubator overnight. The medium and floating cells was aspirated next day. 30ml fresh medium was added to the flask. The flask was returned to the incubator for culture with medium refresh every 3 - 4 days. When cell growth was 80% confluent, cells were sub-cultured to new flasks by 1:10 dilution. The primary fibroblasts of second and third passages were collected, re-suspended in Nutrifreez D10 cryopreservation medium (Biological Industries, Cromwell, CT, USA), aliquoted to 1 ml containing 1 &#215; 10<sup>6</sup> cells in cryovials, frozen and stored in liquid nitrogen.</p></sec><sec id="s2_2"><title>2.2. Fibroblast Expansion</title><p>Human primary fibroblasts were established and stored in liquid nitrogen [<xref ref-type="bibr" rid="scirp.130414-ref14">14</xref>] . Human primary fibroblasts were recovered from liquid nitrogen and cultured in alpha MEM (GIBCO, Carlsbad, CA, USA) containing 5% human platelet lysate (HPL) (Mill Creek Life Sciences, Rochester, MN, USA). When cells grew to 80% full in flask, they were digested with TrypLE expression solution (GIBCO, Carlsbad, CA, USA) and sub-cultured at 37˚C and 5% CO<sub>2</sub>.</p></sec><sec id="s2_3"><title>2.3. Mesenchymal Stromal Cell (MSC) Culture</title><p>BM-MSCs were cultured on laminin-521 coated plates in StemMACS MSC Expansion Medium (Miltenyi Biotec, Germany) at 37˚C and 5% CO<sub>2</sub>. Laminin-521 was purchased from Biolamina Ab, Sweden and the cell culture plates were coated according to the manufacturer’s instructions. For production of EVs, BM-MSCs were cultured until approximately 80% confluency and carefully washed twice with PBS. After that, serum-free Opti-MEM<sup>TM</sup> medium (GIBCO, Carlsbad, CA, USA) was added and the cells were incubated for 48 hours at 37˚C and 5% CO<sub>2</sub>. Then, the conditioned medium was collected, and centrifuged first for 5 minutes at 700 g to remove living cells and a second spin for 100 minutes at 250 g to remove cellular debris. The cells that remain are cultured for 24 hours in the complete culturing medium. Another production round was made as described above.</p></sec><sec id="s2_4"><title>2.4. Isolation of EVs</title><p>The centrifuged conditioned medium was sterile filtered and concentrated using tangential flow filtration (TFF), KR2i TFF system (SpectrumLabs). For that, a modified polyethersulfone (mPES) hollow fiber filter with 300 kDa membrane pore size was used (MidiKros, 370 cm<sup>2</sup> surface area, SpectrumLabs). The flow rate was set at 100 ml/min. At first, the conditioned medium was concentrated to a volume of 75 ml in the container (100 ml total volume in the system) and, then, dialyzed with 1 liter of sterile filtered PBS. After the dialysis, the sample was concentrated to 30 ml and sterilized using a 0.22 &#181;m filter. Finally, the sample was concentrated to a volume of 1 - 2 ml using a 10 ml 10 kDa MWCO spin filter (Amicon).</p></sec><sec id="s2_5"><title>2.5. Western Blotting</title><p>The samples were mixed with Laemmli Sample Buffer (Bio-Rad) under reducing conditions and warmed at 95˚ for 10 min. Then, 4% - 12% gradient gels were used for SDS electrophoresis and the proteins were transferred to polyvinylidene fluoride membranes using iBlot 2 (Invitrogen) according to the manufacturer’s instructions. The membranes were first hybridized with the antibody of interest and, then, with the corresponding HRP-conjugated secondary antibodies. For visualization, chemoluminescent HRP-substrate from Amersham Biosciences was used and the figures were made using ChemiDoc imaging system (Bio-Rad).</p></sec><sec id="s2_6"><title>2.6. Transmission Electron Microscopy</title><p>A 5 &#181;l drop of the sample was placed on a formvar and carbon coated 200-mesh copper grid. The excess solution was removed by blotting with filter paper. The sample was then directly contrasted with 2% uranyl acetate. Excess of uranyl acetate was removed by blotting on filter paper. The contrasting step was repeated twice. Dried grids were examined by Tecnai<sup>TM</sup> G2 Spirit BioTwin transmission electron microscope (Thermo Fisher/FEI) at 80 kV with an ORIUS SC200 CCD camera and Gatan Digital Micrograph software (both from Gatan Inc.).</p></sec><sec id="s2_7"><title>2.7. Detection of Mitochondrial Genes by Polymerase Chain Reaction (PCR)</title><p>Mitochondrially encoded cytochrome c oxidase I (MT-CO1) and mitochondrially encoded NADH dehydrogenase 1 (MT-ND1) in the samples of imEVs were detected by PCR [<xref ref-type="bibr" rid="scirp.130414-ref14">14</xref>] . PCR was performed in a total 25 &#181;l volume including 2 &#181;l of PCR Master mix (Thermofisher Scientific, Waltham, MA, USA), 0.5 &#181;l of 100 &#181;M forward and reverse primers and 1 &#181;l of heat-denatured imEVs samples. The primers for MT-CO1 amplification were 5’-CTAGCAGGTGTCTCCTCTATCT-3’ and 5’-GCTCGTGTGTCTACGTCTATTC-3’. The primers for MT-ND1 were 5’-CCTTCGCTGACGCCATAAA-3’ and 5’-GGTCTCTGCTAGTGTGGAGATA-3’. β-actin (ACTB) was used as endogenous gene control. The primers for ACTB amplification were 5’-CCTTTCTCACTGGTTCTCTCTTC-3’ and 5’-CGTAGCACAGCTTCTCCTTAAT-3’. The amplification procedure included initial DNA denaturing at 95˚C for 3 minutes, then 35 cycles of denaturing 30 seconds at 95˚C, primer annealing 30 seconds at 50˚C and 60 seconds of extension at 72˚C, and final extension of 10 minutes at 72˚C in a T100 Thermal Cycle (Bio-Rad, Hercules, CA, USA). PCR products were run on a 2% agarose gel and imaged by ethidium bromide fluorescence.</p></sec><sec id="s2_8"><title>2.8. Isolation of Mitochondria</title><p>Mitochondrial isolation follows a previously described protocol [<xref ref-type="bibr" rid="scirp.130414-ref14">14</xref>] . All reagents were sterile. Fibroblasts were centrifuged for 5 minutes at 400 g and at 4˚C to remove the media. Cell pellet was re-suspended in ice-cold 300 mM sucrose mitochondrial isolation buffer (MIB) (Sigma Aldrich, St. Louis, MO, USA) and homogenized by bead beating (Bead Ruptor 12, Omni International homogenizer company, Kennesaw, GA, USA). The cell lysate was centrifuged for 10 minutes at 700 g and at 4˚C. Then the supernatant was transferred to new centrifugation tubes and centrifuged for 10 minutes at 9000 g at 4˚C. The supernatant was removed. The wet weight of mitochondria was measured. The mitochondrial pellet was re-suspended with 240 mM sucrose mitochondrial respiration buffer (MRB) (Sigma Aldrich, St. Louis, MO, USA). We mixed the isolated mitochondria of fibroblasts with imEVs (9:1 in volume) and stored the mixture at 2˚C - 6˚C for 2 and 5 days. MMP and mitochondrial ATP content were measured and compared to them of fresh mitochondria (0 day).</p></sec><sec id="s2_9"><title>2.9. Measurement of MMP</title><p>MMP generated by proton pumps is an essential component in the process of energy storage during OXPHOS. Membrane potential dependent dyes such as JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolocarbocyanine iodide) and MitoTracker dyes (rosamine- or cyCarbocyanine-based probes) have been used to stain mitochondria and monitor mitochondrial potential [<xref ref-type="bibr" rid="scirp.130414-ref15">15</xref>] . The stock solution of JC-1 is added to mitochondrial suspension to a final concentration 1 &#181;g/ml. The mixture is incubated for 10 minutes at room temperature. For a control assay, stock solution of valinomycin is added to mitochondrial sample to a final concentration of 10 &#181;g/ml. The mitochondrial sample containing valinomycin is kept on ice for 10 minutes to allow complete dissipation of the MMP. The valinomycin-treated mitochondria are stained with JC-1 dye for 10 minutes at room temperature. Red fluorescent J-aggregates in intact mitochondria can be observed under fluorescent microscope. The relative fluorescence units (RFU) can be read in multiple plate fluorimeter using end-point method with the setting of Ex/Em: 490 nm/590nm.</p></sec><sec id="s2_10"><title>2.10. Measurement of Mitochondrial ATP Content</title><p>ATP content is measured with ATPlite kit (Perkin Elmer Inc., Waltham, MA, USA). The detailed procedure is referred to the product manual. The brief method is as follows: add 50 &#181;l of mammalian cell lysis solution to 100 &#181;l of mitochondria, the mixture of mitochondria with imEVs, or MRB per well in a 96-well plate with white well and clear bottom; shake the plate for 5 minutes; add 50 &#181;l substrate solution to all wells and shake the plate for 5 minutes; measure the luminescence of the plate; calculate ATP content of samples using the ATP standard curve.</p></sec><sec id="s2_11"><title>2.11. Statistical Analysis</title><p>Student’s t-test was used to test statistical significance. p-value less than 0.05 was judged to be of statistical significance.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Characterization of imEVs</title><p>imEVs were characterized according to the International Society for Extracellular Vesicles guidelines. NanoSight 3000 device and transmission electron microscopy revealed the characteristic sizes and shapes for exosomes. The EV samples expressed positive markers of EVs (CD63, CD81, and TSG101) but negative marker of EVs (Calnexin) by using West-blotting.</p></sec><sec id="s3_2"><title>3.2. Viable Mitochondria in imEVs</title><p>imEVs were shipped on dry ice and stored at −20˚C after arrival. At 7 days post-freezing, the imEVs were thawed at 4˚C and stained with JC-1. The mitochondrial genes in the imEVs were determined by PCR. We found intact mitochondria that actively concentrated JC-1 dye in the imEVs sample (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Mitochondrial genes of MT-ND1 and MT-CO1 in the imEVs were amplified by PCR (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The JC-1 staining and PCR confirmed the imEVs contained viable mitochondria. The viable mitochondria maintained MMP even though the imEVs went through freezing-thawing cycles. The viable mitochondria may be apoptotic bodies or free mitochondria in the imEVs solution. The results suggest that imEVs may enhance the stability of extracellular mitochondria.</p></sec><sec id="s3_3"><title>3.3. imEVs Stabilize the Isolated Mitochondrion’s MMP in Cold Storage</title><p>The mitochondria and the mixture of mitochondria with imEVs were stored at</p><p>2˚C - 6˚C for 2 and 5 days. Microscopy showed that the imEVs stimulated aggregation of the isolated mitochondria and maintained MMP, compared to the mitochondria without imEVs (<xref ref-type="fig" rid="fig3">Figure 3</xref>). MMP was measured by a multiple plate fluorimeter using end-point method with the setting of Ex/Em: 490 nm/590nm. The MMP was compared to the MMP of fresh mitochondria (at 0 day). The isolated mitochondria stored at 2˚C - 6˚C for 2 days lost significant MMP (RFU 5458 &#177; 52 at 0 day vs. 1822 &#177; 68 at 2 days, p &lt; 0.01). The MMP at 2 days was approximately 33% of MMP at 0 day. However, the mitochondria mixed with imEVs maintained and even slightly increased the MMP after 2 days of storage at 2˚C - 6˚C (RFU 5962 &#177; 222 at 0 day vs. 6786 &#177; 291 at 2 days, p &gt; 0.05). Mitochondria with imEVs have significantly higher MMP than the mitochondria without imEVs (6786 &#177; 291 vs. 1822 &#177; 68, p &lt; 0.01) after 2 days of preservation at 2˚C - 6˚C (<xref ref-type="table" rid="table1">Table 1</xref>). After 5 days, both the mitochondrial without and with imEVs lost 73% and 70% of MMP (p &lt; 0.01, P &lt; 0.01, compared to fresh mitochondria), respectively (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig4">Figure 4</xref>). The preliminary results showed that imEVs prolonged the survival of isolated mitochondria in cold storage at least 2 days.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> imEVs preserved MMP of isolated mitochondria. The mitochondria were stained with JC-1. RFU was measured by multiple plate fluorimeter using end-point method with the setting of Ex/Em: 490 nm/590nm</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Time Post-isolation</th><th align="center" valign="middle" >0 day</th><th align="center" valign="middle" >2 days</th><th align="center" valign="middle" >5 days</th></tr></thead><tr><td align="center" valign="middle" >Mitochondria (without imEVs)</td><td align="center" valign="middle" >5458 &#177; 52 (3)<sup>1 </sup></td><td align="center" valign="middle" >1822 &#177; 68 (3) (p &lt; 0.01)<sup>2 </sup></td><td align="center" valign="middle" >1490 &#177; 12 (3) (p &lt; 0.01)<sup>2</sup></td></tr><tr><td align="center" valign="middle" >Mitochondria + imEVs (9:1 in volume)</td><td align="center" valign="middle" >5962 &#177; 222 (3) (p &gt; 0.05)<sup>3 </sup></td><td align="center" valign="middle" >6786 &#177; 291 (3) (p &gt; 0.05)<sup>2</sup> (p &lt; 0.01)<sup>3 </sup></td><td align="center" valign="middle" >1838 &#177; 37 (3) (p &lt; 0.01)<sup>2</sup> (p &gt; 0.05)<sup>3</sup></td></tr></tbody></table></table-wrap><p><sup>1</sup>Relative fluorescence units (RFU), mean &#177; standard deviation (SD) (N); <sup>2</sup>Compared to fresh mitochondria (0 day); <sup>3</sup>Compared to the Mitochondria (without imEVs).</p></sec><sec id="s3_4"><title>3.4. imEVs Preserve ATP Content of the Isolated Mitochondria</title><p>In agreement with the MMP, the isolated mitochondria lost approximately 40% ATP content after 2 days cold storage at 2˚C - 6˚C, compared to fresh isolated mitochondria (0 day) (p &lt; 0.01). In contrast, the mitochondria mixed with imEVs maintained approximately 90% ATP content, compared to fresh mitochondria (p &gt; 0.05) (<xref ref-type="table" rid="table2">Table 2</xref>). Mitochondria with imEVs have significantly higher ATP content than the mitochondria without imEVs (90 &#177; 8 vs. 60 &#177; 9, p &lt; 0.05) (<xref ref-type="table" rid="table2">Table 2</xref>). After 5 days of cold storage, mitochondria in both solutions lost significant ATP content (p &lt; 0.01, p &lt; 0.01, respectively, compared to fresh mitochondria) (<xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="fig" rid="fig5">Figure 5</xref>).</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>It has been reported that the isolated mitochondria lost significant activity when stored on ice for more than 1 hour [<xref ref-type="bibr" rid="scirp.130414-ref9">9</xref>] . Thus, clinical applications of mitochondrial transplantation would benefit from improved storage. The development of mitochondrial storage for an extended period is a very important issue [<xref ref-type="bibr" rid="scirp.130414-ref10">10</xref>] . EVs are phospholipid bilayer-enclosed vesicles naturally released from all cell types. EVs carry a cargo of proteins, nucleic acids, lipids, metabolites, and even organelles such as mitochondria from the parent cells [<xref ref-type="bibr" rid="scirp.130414-ref16">16</xref>] . We found viable mitochondria in our imEVs using JC-1 staining and PCR assay even though the imEVs went through freezing-thawing cycles. The findings suggested that EVs preserved the viability of mitochondria that were enclosed in EVs (apoptotic bodies) or outside EVs (mitochondrial contaminants). To confirm the findings, we mixed isolated mitochondria of fibroblasts with imEVs of MSCs as the 9:1 ratio and stored the mitochondrial solutions at 2˚C - 6˚C. After 2 days of storage, the isolated mitochondria without imEVs lost significant MMP and ATP content, but the mitochondria with imEVs addition maintained the almost same of MMP and ATP content as fresh mitochondria. Moreover, imEVs promoted mitochondrial aggregation that might be one of mechanisms to enhance mitochondrial viability. The results suggest that EVs can extend the viability of mitochondria in cold storage at least 2 days.</p><p>Further study remains to be done as the following: 1) ATP production and</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> imEVs enhance the stability of mitochondrial ATP. Mitochondrial ATP content was calculated as the percentage of the fresh isolated mitochondria</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Time Post-isolation</th><th align="center" valign="middle" >0 day</th><th align="center" valign="middle" >2 days</th><th align="center" valign="middle" >5 days</th></tr></thead><tr><td align="center" valign="middle" >Mitochondria without imEVs</td><td align="center" valign="middle" >100 &#177; 0 (3)<sup>1 </sup></td><td align="center" valign="middle" >60 &#177; 9 (3) (p &lt; 0.01)<sup>2 </sup></td><td align="center" valign="middle" >30 &#177; 6 (3) (p &lt; 0.01)<sup>2</sup></td></tr><tr><td align="center" valign="middle" >Mitochondria + imEVs (9:1 in volume)</td><td align="center" valign="middle" >100 &#177; 0 (3) (p &gt; 0.05)<sup>3 </sup></td><td align="center" valign="middle" >90 &#177; 8 (3) (p &gt; 0.05)<sup>2</sup> (p &lt; 0.05)<sup>3 </sup></td><td align="center" valign="middle" >42 &#177; 7 (3) (p &lt; 0.01)<sup>2</sup> (p &gt; 0.05)<sup>3</sup></td></tr></tbody></table></table-wrap><p><sup>1</sup>Mitochondrial ATP content, % fresh mitochondria (0 day), mean &#177; standard deviation (SD) (N); <sup>2</sup>Compared to fresh mitochondria (0 day); <sup>3</sup>Compared to the Mitochondria without imEVs.</p><p>oxygen consumption of mitochondria with and without imEVs using Seahorse system; 2) Are mitochondria packed into imEVs or only trapped in the matrix of imEVs? 3) What the optimal ratio of mitochondria to imEVs to extend the survival of the mitochondria? 4) Do imEVs change the ability of mitochondrial transplant to cells? Our current results are preliminary but provide a potential new preservation method to extend the life of isolated mitochondria for MOT application.</p></sec><sec id="s5"><title>Acknowledgements</title><p>We would like to thank Karin Stax&#228;ng and Monika Hodik from BioVis Facility, Uppsala University, Sweden for the help with transmission electron microscopy. We would like to thank BSc Alice T&#246;rne from the Cardio-Thoracic Translational Medicine lab, Uppsala University, Sweden for the help with Western-blot analysis. This work was supported by the Centre for Advanced Therapy Medicinal Products (CAMP)/Vinnova, Sweden (https://atmpsweden.se/).</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>Xianpeng Jiang, Catherine C. Baucom and Brent Segal have research support from MitoSense Inc. and also serve on the Board of Directors of MitoSense Inc.. Dr. Sergey Rodin and Dr. Karl-Henrik Grinnemo are co-owners of the company AVulotion AB.</p></sec><sec id="s7"><title>Cite this paper</title><p>Jiang, X.P., Rodin, S., Braesch-Andersen, K., Baucom, C.C., Grinnemo, K.-H. and Segal, B. (2024) Extracellular Vesicles from Mesenchymal Stromal Cells (imEVs) Improve Cold Preservation of Isolated Mitochondria. Journal of Biosciences and Medicines, 12, 52-63. https://doi.org/10.4236/jbm.2024.121005</p></sec></body><back><ref-list><title>References</title><ref id="scirp.130414-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Murphy, E., Ardehali, H., Balaban, R.S., DiLisa, F., DornII, G.W., et al. (2016) Mitochondrial Function, Biology, and Role in Disease. Circulation Research, 118, 1960-1991. https://doi.org/10.1161/RES.0000000000000104.</mixed-citation></ref><ref id="scirp.130414-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Braymer, J.J. and Lill, R. (2017) Iron-Sulfur Cluster Biogenesis and Trafficking in Mitochondria. Journal of Biological Chemistry, 292, 12754-12763. https://doi.org/10.1074/jbc.R117.787101</mixed-citation></ref><ref id="scirp.130414-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Herst, P.M., Rowe, M.R., Carson, G.M. and Berridge, M.V. (2017) Functional Mitochondria in Health and Disease. Frontiers in Endocrinology, 9, 1-16. https://doi.org/10.3389/fendo.2017.00296.</mixed-citation></ref><ref id="scirp.130414-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Smith, E.F., Shaw, P.J. and De Vos, K.J. (2019) The Role of Mitochondria in Amyotrophic Lateral Sclerosis. Neuroscience Letters, 710, Article ID: 132933. https://doi.org/10.1016/j.neulet.2017.06.052</mixed-citation></ref><ref id="scirp.130414-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Federico, A., Cardaioli, E., Pozzo, P.D., Formichi, P., Gallus, G.N. and Radi, E. (2012) Mitochondria, Oxidative Stress and Neurodegeneration. Journal of the Neurological Sciences, 322, 254-262. https://doi.org/10.1016/j.jns.2012.05.030</mixed-citation></ref><ref id="scirp.130414-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Elliott, R. and Jiang, X. (2020) Neurodegeneration and Mitochondria Organelle Transplantation: “A Technology That Proof of Principle Suggest Is Ready for Prime Time”. Neuroscience and Medicine, 11, 108-118. https://doi.org/10.4236/nm.2020.114013</mixed-citation></ref><ref id="scirp.130414-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Norat, P., Soldozy, S., Sokolowski, J.D., Gorick, C.M., et al. (2020) Mitochondrial Dysfunction in Neurological Disorders: Exploring Mitochondrial Transplantation. npj Regenerative Medicine, 5, Article No. 22. https://doi.org/10.1038/s41536-020-00107-x</mixed-citation></ref><ref id="scirp.130414-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Emani, S.M., Piekarski, B.L., Harrild, D., Del Nido, P.J. and McCully, J.D. (2017) Autologous Mitochondrial Transplantation for Dysfunction after Ischemia-Reperfusion Injury. The Journal of Thoracic and Cardiovascular Surgery, 154, 286-289. https://doi.org/10.1016/j.jtcvs.2017.02.018</mixed-citation></ref><ref id="scirp.130414-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">McCully, J.D., Cowan, D.B., Emani, S.M. and Del Nido, P.J. (2017) Mitochondrial Transplantation: From Animal Models to Clinical Use in Humans. Mitochondrion, 34, 127-134. https://doi.org/10.1016/j.mito.2017.03.004</mixed-citation></ref><ref id="scirp.130414-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Yamada, Y., Momo Ito, M., Arai, M., Hibino, M., Tsujioka, T. and Harashima, H. (2020) Challenges in Promoting Mitochondrial Transplantation Therapy. International Journal of Molecular Sciences, 21, Article 6365. https://doi.org/10.3390/ijms21176365</mixed-citation></ref><ref id="scirp.130414-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Murphy, D.E., de Jong, O.G., Brouwer, M., Wood, M.J., Lavieu, G., Schiffelers, R.M. and Pieter Vader, P. (2019) Extracellular Vesicle-Based Therapeutics: Natural versus Engineered Targeting and Trafficking. Experimental &amp; Molecular Medicine, 51, 1-12. https://doi.org/10.1038/s12276-019-0223-5</mixed-citation></ref><ref id="scirp.130414-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Battistelli, M. and Falcieri, E. (2020). Apoptotic Bodies: Particular Extracellular Vesicles Involved in Intercellular Communication. Biology, 9, Article 21.https://doi.org/10.3390/biology9010021</mixed-citation></ref><ref id="scirp.130414-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Silva, J.D., Yue Su, Calfee, C.S., Delucchi, K.L., Weiss, D., McAuley, D.F., O’Kane, C. and Krasnodembskaya, A.D. (2021) Mesenchymal Stromal Cell Extracellular Vesicles Rescue Mitochondrial Dysfunction and Improve Barrier Integrity in Clinically Relevant Models of ARDS. European Respiratory Journal, 58, Article ID: 2002978. https://doi.org/10.1183/13993003.02978-2020</mixed-citation></ref><ref id="scirp.130414-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, X. , Baucom, C. and Elliott, R. (2020) Mitochondria Dynamically Transplant into Cells in Vitro and in Mice and Rescue Aerobic Respiration of Mitochondrial DNA-Depleted Motor Neuron NSC-34. Journal of Biomedical Science and Engineering, 13, 203-221. https://doi.org/10.4236/jbise.2020.139019</mixed-citation></ref><ref id="scirp.130414-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Sivandzade, F., Bhalerao, A. and Cucullo, L. (2019) Analysis of the Mitochondrial Membrane Potential Using the Cationic JC-1 Dyeas a Sensitive Fluorescent Probe. Bio Protocol, 9, e3128. https://doi.org/10.21769/BioProtoc.3128</mixed-citation></ref><ref id="scirp.130414-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Elsharkasy, O.M., Nordin, J.Z., Hagey, D.W., de Jong, O.G., Schiffelers, R.M., Andaloussi, S.E. and Vader, P. (2020) Extracellular Vesicles as Drug Delivery Systems: Why and How? Advanced Drug Delivery Reviews, 159, 332-343. https://doi.org/10.1016/j.addr.2020.04.004.</mixed-citation></ref></ref-list></back></article>